Therapeutic antibodies: A new era in the treatment of respiratory diseases?

ABSTRACT Respiratory diseases affect millions of people worldwide, and account for significant levels of disability and mortality. The treatment of lung cancer and asthma with therapeutic antibodies (Abs) is a breakthrough that opens up new paradigms for the management of respiratory diseases. Antibodies are becoming increasingly important in respiratory medicine; dozens of Abs have received marketing approval, and many more are currently in clinical development. Most of these Abs target asthma, lung cancer and respiratory infections, while very few target chronic obstructive pulmonary disease ‐ one of the most common non‐communicable causes of death – and idiopathic pulmonary fibrosis. Here, we review Abs approved for or in clinical development for the treatment of respiratory diseases. We notably highlight their molecular mechanisms, strengths, and likely future trends.

• Publication year

  2018

• Venue

  Pharmacology and Therapeutics

• Publication date

  2018-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.pharmthera.2018.05.003PMID 29730443
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Innate lymphoid cells at the interface between obesity and asthma

  2018cited by this paper
• Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs

  2018cited by this paper
• Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.

  2018cited by this paper
• Tezepelumab in Adults with Uncontrolled Asthma

  2017cited by this paper
• "Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis.

  2017cited by this paper
• Comparison of Interleukin-33 Serum Levels in Asthmatic Patients with a Control Group and Relation with the Severity of the Disease

  2017cited by this paper
• A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis

  2017cited by this paper
• Personalised medicine in asthma: from curative to preventive medicine

  2017cited by this paper
• Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy

  2017cited by this paper
• A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease

  2017cited by this paper
• Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review

  2017cited by this paper
• Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

  2017cited by this paper
• Care pathways for the selection of a biologic in severe asthma

  2017cited by this paper
• Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer

  2017cited by this paper
• Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

  2017cited by this paper
• Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

  2017cited by this paper
• Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model

  2017cited by this paper
• Strategies and challenges for the next generation of antibody–drug conjugates

  2017cited by this paper
• Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)

  2017cited by this paper
• Characteristics of severe asthma with fungal sensitization.

  2017cited by this paper
• Airway basophils are increased and activated in eosinophilic asthma

  2017cited by this paper
• Understanding Interleukin 33 and Its Roles in Eosinophil Development

  2017cited by this paper
• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

  2017cited by this paper
• The fate of inhaled antibiotics after deposition in cystic fibrosis: How to get drug to the bug?

  2017cited by this paper
• IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies.

  2017cited by this paper
• Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.

  2017cited by this paper
• Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015

  2017cited by this paper
• A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers.

  2017cited by this paper
• The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases

  2017cited by this paper
• Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope

  2017cited by this paper
• New concepts in asthma: clinical phenotypes and pathophysiological mechanisms.

  2017cited by this paper
• COPD: JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

  2017cited by this paper
• Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.

  2017cited by this paper
• OA 14.05 Phase 2 Basket Trial of Ado-Trastuzumab Emtansine in Patients with HER2 Mutant or Amplified Lung Cancers

  2017cited by this paper
• KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa.

  2017cited by this paper
• Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.

  2016cited by this paper
• Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma

  2016cited by this paper
• Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.

  2016cited by this paper
• Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin.

  2016cited by this paper
• Immunoglobulin E, what is it good for?

  2016cited by this paper
• Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.

  2016cited by this paper
• Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.

  2016cited by this paper
• Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma

  2016cited by this paper
• Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.

  2016cited by this paper
• Increased volume of conducting airways in idiopathic pulmonary fibrosis is independent of disease severity: a volumetric capnography study

  2016cited by this paper
• Reslizumab: First Global Approval

  2016cited by this paper
• Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax

  2016cited by this paper
• Lebrikizumab for the treatment of asthma

  2016cited by this paper
• Pulmonary mucosa-associated lymphoid tissue lymphoma revisited

  2016cited by this paper
• Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma

  2016cited by this paper
• Blockade of IL-23 ameliorates allergic lung inflammation via decreasing the infiltration of Tc17 cells

  2016cited by this paper
• Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults

  2016cited by this paper
• Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.

  2016cited by this paper
• Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.

  2016cited by this paper
• A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma

  2016cited by this paper
• Biomarkers in the clinical development of asthma therapies.

  2016cited by this paper
• Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.

  2016cited by this paper
• IL-33 Precedes IL-5 in Regulating Eosinophil Commitment and Is Required for Eosinophil Homeostasis

  2016cited by this paper
• Abstract CT027: A phase I, open-label study of GSK3174998 administered alone and in combination with pembrolizumab in patients (pts) with selected advanced solid tumors (ENGAGE-1)

  2016cited by this paper
• A first-in-human (FIH) study of PF-04518600 (PF-8600) OX40 agonist in adult patients (pts) with select advanced malignancies

  2016cited by this paper
• Emerging therapeutic agents for lung cancer

  2016cited by this paper
• Harnessing T cells to fight cancer with BiTE® antibody constructs – past developments and future directions

  2016cited by this paper
• Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

  2016cited by this paper
• Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma.

  2016cited by this paper
• Novel Biologicals for the Treatment of Allergic Diseases and Asthma

  2016cited by this paper
• Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study

  2016cited by this paper
• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

  2016cited by this paper
• Coagulation and anticoagulation in idiopathic pulmonary fibrosis

  2015cited by this paper
• The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.

  2015cited by this paper
• Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?

  2015cited by this paper
• Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients

  2015cited by this paper
• Nebulization as a delivery method for mAbs in respiratory diseases

  2015cited by this paper
• Mepolizumab: First Global Approval

  2015cited by this paper
• The Role of Type 2 Inflammation in the Pathogenesis of Asthma Exacerbations.

  2015cited by this paper
• Distinct effects of endogenous interleukin-23 on eosinophilic airway inflammation in response to different antigens.

  2015cited by this paper
• A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases.

  2015cited by this paper
• CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab

  2015cited by this paper
• Discovery of PRS-060, an inhalable CD123/IL4Ra/TH2 blocking anti-asthmatic anticalin protein re-engineered from endogenous lipocalin-1

  2015cited by this paper
• Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.

  2015cited by this paper
• Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.

  2015cited by this paper
• Challenges and opportunities for non-antibody scaffold drugs.

  2015cited by this paper
• Specificity of human anti‐variable heavy (VH) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor‐α receptor 1

  2015cited by this paper
• Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

  2015cited by this paper
• CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors

  2015cited by this paper
• Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

  2015cited by this paper
• Structure and dynamics of IgE–receptor interactions: FcεRI and CD23/FcεRII

  2015cited by this paper
• First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

  2015cited by this paper
• Summary health statistics for U.S. adults: national health interview survey, 2012.

  2014cited by this paper
• A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

  2014cited by this paper
• Subcutaneous administration of anticancer agents.

  2014cited by this paper
• Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia

  2014cited by this paper
• Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity

  2014cited by this paper
• Omalizumab in asthma: an update on recent developments.

  2014cited by this paper
• Extracellular matrix proteins: a positive feedback loop in lung fibrosis?

  2014cited by this paper
• MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.

  2014cited by this paper

• Effects of Pharmacological Treatment on Telomere Length and the Expression of Telomerase/Shelterin-Related Genes in Rat Models of Autism

  2025cites this paper
• Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy

  2024cites this paper
• Detection of serum CC16 by a rapid and ultrasensitive magnetic chemiluminescence immunoassay for lung disease diagnosis

  2024cites this paper
• Strategies for Quorum Sensing inhibition as a tool for controlling Pseudomonas aeruginosa infections.

  2024cites this paper
• Assessment of epithelial lining fluid partitioning of systemically administered monoclonal antibodies in rats.

  2023cites this paper
• The proteolytic airway environment associated with pneumonia acts as a barrier for treatment with anti-infective antibodies.

  2023cites this paper
• Osteopontin: A Novel Therapeutic Target for Respiratory Diseases

  2023cites this paper
• Systemically Administered Anti-uPAR Antibody Plasma and Lung ELF Pharmacokinetics Characterized by Minimal Lung PBPK Model

  2023cites this paper
• Mucosal administration of anti-bacterial antibody provides long-term cross-protection against Pseudomonas aeruginosa respiratory infection.

  2023cites this paper
• Therapeutic Antibodies in Medicine

  2023influential citation
• Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates

  2023cites this paper
• Aerosolization Performance of Immunoglobulin G by Jet and Mesh Nebulizers

  2023cites this paper
• A new hope? Possibilities of therapeutic IgA antibodies in the treatment of inflammatory lung diseases

  2023cites this paper
• Biotherapeutics ADME and PK/PD Principles

  2022cites this paper
• Therapeutic Antibodies: An Overview.

  2022cites this paper
• Inhaled antibodies: formulations require specific development to overcome instability due to nebulization

  2021cites this paper
• Preservation of mitochondrial homeostasis is responsible for the ameliorative effects of Suhuang antitussive capsule on non-resolving inflammation via inhibition of NF-κB signaling and NLRP3 inflammasome activation.

  2021cites this paper
• The Potential for Phospholipids in the Treatment of Airway Inflammation: An Unexplored Solution.

  2021cites this paper
• Therapeutic Antibodies for the Treatment of Respiratory Tract Infections—Current Overview and Perspectives

  2021influential citation
• Inhalable Protein Powder Prepared by Spray-Freeze-Drying Using Hydroxypropyl-β-Cyclodextrin as Excipient

  2021cites this paper
• Evaluation of the effectiveness of infectious diseases immunoprophylaxis (review of our own research on the model of tick-borne encephalitis)

  2021cites this paper
• Ethnobotanical Survey of Plants Used for Treating Cough Associated with Respiratory Conditions in Ede South Local Government Area of Osun State, Nigeria

  2020cites this paper
• Protein stability during nebulization: mind the collection step!

  2020cites this paper
• Advances in the use of cell penetrating peptides for respiratory drug delivery

  2020cites this paper
• [Intrapulmonary Pharmacokinetics and Drug Distribution Characteristics for the Treatment of Respiratory Diseases].

  2020cites this paper
• Correlation and clinical relevance of animal models for inhaled pharmaceuticals and biopharmaceuticals.

  2020cites this paper
• Making Concentrated Antibody Formulations Accessible for Vibrating-Mesh Nebulization.

  2019cites this paper
• RNA therapy: Are we using the right molecules?

  2019cites this paper
• Neoantigens in Chronic Obstructive Pulmonary Disease and Lung Cancer: A Point of View

  2019cites this paper
• Monoclonal antibodies for severe asthma: Pharmacokinetic profiles.

  2019cites this paper
• In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration.

  2019cites this paper
• [Severe asthma revisited by biologic therapies emergences].

  2019cites this paper
• Targeting Aspergillus fumigatus Crf Transglycosylases With Neutralizing Antibody Is Relevant but Not Sufficient to Erase Fungal Burden in a Neutropenic Rat Model

  2019cites this paper
• Designing inhaled protein therapeutics for topical lung delivery: what are the next steps?

  2018cites this paper
• Recent advances in mixed-mode chromatographic stationary phases.

  2018cites this paper